Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-01-08
2008-01-08
Anderson, Rebecca (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S352000, C514S367000, C514S370000, C514S377000, C514S383000, C514S407000, C546S176000, C546S285000, C548S160000, C548S190000, C548S233000, C548S264800, C548S326500, C548S371400
Reexamination Certificate
active
07317024
ABSTRACT:
The invention relates to a class of novel non-steroidal compounds which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of formula (I)or stereoisomers or prodrugs or solvates or pharmaceutically acceptable salts thereof, wherein Z, R, R4, R5, Ra, Rb, Rc, and Rd, are defined herein. Also provided are pharmaceutical compositions and methods of treating obesity, diabetes and inflammatory or immune associated diseases comprising said compounds.
REFERENCES:
patent: 3317387 (1967-05-01), Prichard
patent: 3422104 (1969-01-01), Schröter et al.
patent: 3517073 (1970-06-01), Fields
patent: 4786646 (1988-11-01), Guthrie et al.
patent: 5055468 (1991-10-01), Gray et al.
patent: 5202486 (1993-04-01), Barrish et al.
patent: 5332820 (1994-07-01), Duncia
patent: 5409932 (1995-04-01), Schwenner et al.
patent: 5411960 (1995-05-01), Schwenner et al.
patent: 5455248 (1995-10-01), DeHaven-Hudkins et al.
patent: 5514683 (1996-05-01), Kalindjian et al.
patent: 5569655 (1996-10-01), Dority, Jr. et al.
patent: 5616780 (1997-04-01), Pitteloud et al.
patent: 6214915 (2001-04-01), Avakian et al.
patent: 6262059 (2001-07-01), Pamukcu et al.
patent: 6291679 (2001-09-01), Mailliet et al.
patent: 6995181 (2006-02-01), Vaccaro et al.
patent: 2005/0182110 (2005-08-01), Yang
patent: 198 678 (1982-11-01), None
patent: 197 42 014 (1999-03-01), None
patent: 0 405 436 (1995-11-01), None
patent: WO 93/16982 (1993-09-01), None
patent: WO 94/00421 (1994-01-01), None
patent: WO 95/05359 (1995-02-01), None
patent: WO 95/15947 (1995-06-01), None
patent: WO 99/15493 (1999-04-01), None
patent: WO 02/051851 (2002-07-01), None
patent: WO 03/062241 (2003-07-01), None
patent: WO 03/101932 (2003-12-01), None
patent: WO 03/104195 (2003-12-01), None
patent: WO 2004/000869 (2003-12-01), None
patent: WO 2004/005229 (2004-01-01), None
patent: WO 2004/009017 (2004-01-01), None
patent: WO 2005/070207 (2005-08-01), None
patent: WO 2005/072729 (2005-08-01), None
patent: WO 2005/072732 (2005-08-01), None
patent: WO 2005/073221 (2005-08-01), None
patent: 681802 (1968-03-01), None
Alibert, S. et al., “Synthesis and Effects on Chloroquine Susceptibility inPlasmodium falciparumof a Series of New Dihydroanthracene Derivatives”, Journal of Medicinal Chemistry, vol. 45, No. 15, pp. 3195-3209 (2002).
Baldwin, Jr., A.S., “The transcription factor NF-κB and human disease”, The Journal of Clinical Investigation, vol. 107, No. 1, pp. 3-6 (2001).
Bradsher, C.K. et al., “Acridizinium Ion Chemistry, II. The Diels-Alder Reaction”, Journal of the American Chemical Society, vol. 80, pp. 933-934 (1958).
Bradsher, C.K. et al., “Addition of Dienophiles to the Acridizinium Ion. III. Evidence for a Two-Step Reaction”, The Journal of Organic Chemistry, vol. 34, No. 6, pp. 1700-1702 (1969).
Bradsher, C.K. et al., “Cationic Polar Cycloaddition of Cyclopropenes”, J. Org. Chem., vol. 44, No. 8, pp. 1199-1202 (1979).
Bradsher, C.K. et al., “Possible Role of Charge-Transfer Complexes in Cationic Polar Cycloaddition”, J. Org. Chem., vol. 43, No. 5, pp. 822-827 (1978).
Bradsher, C.K. et al., “Stereoselectivity Due to Electrostatic Repulsion in the Polar Cycloaddition of the Acridizinium Ion”, J. Het. Chem., vol. 10, pp. 1031-1033 (1973).
Bradsher, C.K. et al., “Steric Effects in Some Cycloaddition Reactions”, Journal of the American Chemical Society, vol. 99, No. 8, pp. 2588-2591 (1977).
Bradsher, C.K. et al., “The Nature of the Addition of Dienophiles to the Acridizinium Ion”, The Journal of Organic Chemistry, vol. 33, No. 2, pp. 519-523 (1968).
Burke, J.R., “Targeting IκB kinase for the treatment of inflammatory and other disorders”, Current Opinion in Drug Discovery & Development, vol. 6, No. 5, pp. 720-728 (2003).
Burnham, W.S. et al., “6,11-Dihydroacridizinium Derivatives Having a 6,11-Etheno Bridge”, J. Org. Chem., vol. 37, No. 3, pp. 355-358 (1972).
Butler, D.N. et al., “Chemistry of Proximal π-Bond Systems. Part I. Synthesis of Vicinal Exocyclic Dimethylene Hydrocarbons”, Canadian Journal of Chemistry, vol. 50, pp. 795-802 (1972).
Caldenhoven, E. et al., “Negative Cross-Talk between ReIA and the Glucocorticoid Receptor: A Possible Mechanism for the Antiinflammatory Action of Glucocorticoids”, Molecular Endocrinology, vol. 9, No. 4, pp. 401-412 (1995).
Chakravarti, D. et al., “Role of CBP/P300 in nuclear receptor signalling”, Nature, vol. 383, pp. 99-103 (1996).
Compounds (by Registry Number) with no references in the Chemical Abstracts file: 500280-08-0, 496959-82-1, 332907-97-8, 331751-07-6, 331427-65-7, 312317-98-9, 312315-55-2, 311331-77-8.
Diamond, M.I. et al., “Transcription Factor Interactions: Selectors of Positive or Negative Regulation from a Single DNA Element”, Science, vol. 249, pp. 1266-1272 (1990).
El-Zanfally, S. et al., “Reactions of Aminopyridines with some Inner Anhydrides”, Egypt J. Pharm. Sci., vol. 17, No. 3, pp. 53-62 (1976).
Fields, D.L., “A Novel Synthesis of 2-Naphthols, Phenanthrols, Anthracenes, and Other Polycyclic Aromatic Products”, J. Org. Chem., vol. 36, No. 20, pp. 3002-3005 (1971).
Fields, D.L. et al., “Azonia Polycyclic Quinones,o-Diazo-Oxides and Related Products”, J. Het. Chem., vol. 7, pp. 91-97 (1970).
Fields, D.L. et al., “Cleavage Reactions of Bicyclic Ketones Derived from Azoniaanthracene-Ketene Acetal Adducts”, J. Org. Chem., vol. 35, No. 6, pp. 1870-1875 (1970).
Fields, D.L. et al., “Diels-Alder Reactions Involving Azonia Polycyclic Aromatic Compounds and Nucleophilic Dienophiles”, J. Org. Chem., vol. 33, No. 1, pp. 390-395 (1968).
Fields, D.L. et al., “Overcrowded Molecules. I. Substituted 8-tert-Butyl-1-(2-pyridyl)naphthalenes, Including a Thermodynamically Stable Ketonic Tautomer”, J. Org. Chem., vol. 36, No. 20, pp. 2986-2990 (1971).
Fields, D.L. et al., “Overcrowded Molecules. II. 4,5-Bis(2-pyridyl)phenanthrene-3,6-diols”, J. Org. Chem., vol. 36, No. 20, pp. 2991-2995 (1971).
Fields, D.L. et al., “Overcrowded Molecules. III. 13, 14-Bis(2-pyridyl)pentaphene and Related Compounds”, J. Org. Chem., vol. 36, No. 20, pp. 2995-3001 (1971).
Firestein, G.S. et al., “Signal Transduction and Transcription Factors in Rheumatic Disease”, Arthritis & Rheumatism, vol. 42, No. 4, pp. 609-621 (1999).
Hart, H. et al., “1,4,5,8,9-pentamethylanthracene, Synthesis and Protonation”, Tetrahedron Letters, vol. 16, No. 52, pp. 4639-4642 (1975).
Jackson, R.W. et al., “Benzobicyclooctanes as Novel Inhibitors of TNF-α Signaling”, Bioorganic & Medicinal Chemistry Letters, vol. 12, pp. 1093-1097 (2002).
Jonat, C. et al., “Antitumor Promotion and Antiinflammation: Down-Modulation of AP-1 (Fos/Jun) Activity by Glucocorticoid Hormone”, Cell, vol. 62, pp. 1189-1204 (1990).
Kamei, Y. et al., “A CBP Integrator Complex Mediates Transcriptional Activation and AP-1 Inhibition by Nuclear Receptors”, Cell, vol. 85, pp. 403-414 (1996).
Kotha, S. et al., “Synthesis of highly constrained unusual α-amino acid derivative by the Diels-Alder approach”, Indian Journal of Chemistry, vol. 41B, pp. 2330-2332 (2002).
Manning, A.M. et al., “Targeting JNK for Therapeutic Benefit: From Junk to Gold”, Nature Reviews Drug Discovery, vol. 2, pp. 554-565 (2003).
Miesfeld, R. et al., “Characterization of a steroid hormone receptor gene and mRNA in wild-type and mutant cells”, Nature, vol. 312, pp. 779-781 (1984).
Parham, M.E. et al., “The Cycloaddition of the Acridizinium Ion with Norbornene Derivatives”, J. Org. Chem., vol. 37, No. 3, pp. 358-362 (1972).
Peltz, G., “Transcription factors in immune-mediated disease&#x
Anderson Rebecca
Bristol-Myers Squibb Co.
Cheng Karen
Duncan Laurelee A.
LandOfFree
Heterocyclic modulators of the glucocorticoid receptor,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heterocyclic modulators of the glucocorticoid receptor,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclic modulators of the glucocorticoid receptor,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2749191